Status:
COMPLETED
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It works by acting on cells in the lun...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- male or female (of non-childbearing potential) between 18 - 70 years
- History of stable mild to moderate asthma
- non - smokers
- currently taking daily doses of inhaled fluticasone propionate 200 - 500 mcg (or equivalent)
- body weight \>50 kg with BMI 19-29.9 kg/m2
- normal ECG assessment
- Exclusion criteria:
- history of significant disease
- history of life threatening asthma
- recent respiratory tract infection
- recent change of asthma medication
- treatment with high dose inhaled corticosteroids or oral corticosteroids
- recent participation in another trial
- history of drug or alcohol abuse
- known allergies (excluding asthma)
- recent blood donation
Exclusion
Key Trial Info
Start Date :
April 2 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00463697
Start Date
April 2 2007
End Date
August 4 2007
Last Update
August 7 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ
2
GSK Investigational Site
London, United Kingdom, SE1 1YR
3
GSK Investigational Site
Manchester, United Kingdom, M23 9QZ